Gao, Pan
Inada, Yoshiko
Hotta, Akitsu
Sakurai, Hidetoshi
Ikeya, Makoto http://orcid.org/0000-0002-3930-8032
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP15bm0104001, 23bm1323001h0001, JP22bm1123006)
Hyogo Science and Technology Association (5024)
Kyoto University Foundation
iPS Cell Research Fund
China Scholarship Council (202008510007)
Article History
Received: 29 September 2023
Accepted: 7 March 2024
First Online: 18 March 2024
Declarations
:
: All experimental protocols dealing with human subjects were approved by the ethics committee of the Department of Medicine and Graduate School of Medicine of Kyoto University (The Generation of Human Disease-Specific iPS Cells and the Use of Such iPS Cells for Disease Analysis (R0091, 06/04/2008)). Written informed consent was provided by each donor. All animal experiments were approved by the institutional animal committee of Kyoto University (Research on development of regenerative medicine using pluripotent stem cell-derived stem cells (#16–73, 04/01/2016–03/31/2022), Ectopic bone origin exploration study using model mice (#22–154, 04/01/2022–), Development of a treatment for fibrodysplasia ossificans progressiva using a mouse model (#23–218, 08/22/2023–).
: Not applicable.
: The authors declare no competing interests.